TAG-72 Antibody (0.N.561A): sc-73108

TAG-72 Antibody (0.N.561A) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) with broad species reactivity through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein primarily localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for various cancers. Expression of TAG-72 is notably high in approximately 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues and benign conditions, making TAG-72 a significant target for cancer diagnostics and therapeutics. TAG-72 is also expressed in several gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas, and TAG-72 presence in human prostatic adenocarcinomas has been shown to negatively correlate with the Gleason grade of differentiation, indicating potential as a prognostic marker. Furthermore, TAG-72 is highly expressed in low-grade mucoepidermoid carcinomas, while being absent in pure squamous cell mucoepidermoid carcinomas, highlighting specificity in cancer detection. TAG-72′s ability to aid in the purification of primary ovarian cancer cells from patient ascites further underscores importance in cancer research and treatment strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (0.N.561A) References:

1. Epithelial cells from normal human endometrium express a tumor-associated glycoprotein (TAG-72) epitope in vitro.  |  Osteen, KG., et al. 1990. Am J Obstet Gynecol. 163: 479-84. PMID: 1696780
2. Clinical evaluation of the new tumor marker TAG-72.  |  Guadagni, F., et al. 1991. Anticancer Res. 11: 1389-94. PMID: 1746895
3. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.  |  Soper, JT., et al. 1990. Am J Obstet Gynecol. 163: 1204-9. PMID: 2220931
4. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas.  |  Katari, RS., et al. 1990. Cancer Res. 50: 4885-90. PMID: 2379152
5. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary.  |  Einhorn, N., et al. 1989. Acta Oncol. 28: 655-7. PMID: 2590540
6. Detection of the tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon.  |  Wolf, BC., et al. 1989. J Natl Cancer Inst. 81: 1913-7. PMID: 2593169
7. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.  |  Gadducci, A., et al. 1989. J Nucl Med Allied Sci. 33: 32-6. PMID: 2746365
8. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.  |  Ohuchi, N., et al. 1989. Jpn J Clin Oncol. 19: 242-8. PMID: 2810823
9. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.  |  Takasaki, H., et al. 1988. Int J Cancer. 42: 681-6. PMID: 3053465
10. Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer.  |  Chung, JK., et al. 1995. Ann Nucl Med. 9: 7-13. PMID: 7779533

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.